Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Short Interest Jumps 183.4%

Key Points

• Short interest surged 183.4% to 360,790 shares as of September 15, up from 127,301 shares at the end of August. Short interest represents approximately 0.0% of shares, with a short-interest ratio of 0.6 days.
• Analysts remain broadly positive on Bayer, with two Strong Buy ratings, five Buy ratings and one Hold rating, producing an overall “Buy” consensus. Zacks Research and Deutsche Bank recently upgraded the stock.
• Bayer reported quarterly EPS of $0.29, beating estimates of $0.23, while revenue reached $12.53 billion. The company issued fiscal 2026 EPS guidance of $1.200 to $1.346.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totaling 360,790 shares, a growth of 183.4% from the August 31st total of 127,301 shares. Approximately 0.0% of the company's stock are short sold. Based on an average trading volume of 590,511 shares, the short-interest ratio is currently 0.6 days.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Thursday, July 2nd. Finally, Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a "hold" rating in a research report on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy".

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS BAYRY opened at $14.32 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $56.28 billion, a price-to-earnings ratio of -28.08, a price-to-earnings-growth ratio of 2.12 and a beta of 0.56. Bayer Aktiengesellschaft has a twelve month low of $7.48 and a twelve month high of $15.23. The business has a 50 day simple moving average of $14.00 and a 200-day simple moving average of $12.44.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm had revenue of $12.53 billion for the quarter, compared to analysts' expectations of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities research analysts expect that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer's American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, neurology and specialty therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.